Homepage Top Section1

This partnership is set to enhance the treatment options available to diabetes patients in Brazil. Under the agreement, Biocon will be responsible for the development, manufacturing, and supply

This sNDA extends the indication of Vemlidy, a once a day 25mg tablet for usage in children aged six years and above weighing a minimum of 25kg with

The facility, which is part of the company’s strategic growth plan, aims to enhance pharmaceutical development and manufacturing offerings in Asia. This will aid in meeting the increasing

In October this year, Lilly signed a definitive agreement for POINT Biopharma acquisition. POINT Biopharma focuses on developing radioligand treatments for cancer and has a pipeline of such

Currently, SLS009 is under evaluation in a Phase Ib/II trial for patients with r/r PTCL. The study, which is open-label and single-arm, plans to enrol up to 95

This marks Nefecon as the first FDA-approved treatment for IgAN. Nefecon is an oral, delayed-release formulation of budesonide, a corticosteroid with potent anti-inflammatory properties. The enteric-coated capsule approval

ATX101 is designed for sustained, localised pain relief post total knee arthroplasty surgery. Under the agreement, Allay will receive an upfront payment and equity investment. It is also

Under the agreement, Maruho will be responsible for the development and commercialisation of Qbrexza in South Korea, Brunei, Cambodia, Indonesia, Hong Kong, Macau, Vietnam, Malaysia, Philippines, Thailand, Myanmar,

The first-in-class C5 complement inhibitor, Soliris has been indicated for anti-acetylcholine receptor antibody-positive children and adolescents aged six to 17 years. It is claimed to be the first